Literature DB >> 12172137

Outcome of patients with toxic epidermal necrolysis syndrome revisited.

Ivica Ducic1, Avshalom Shalom, William Rising, Ken Nagamoto, Andrew M Munster.   

Abstract

Toxic epidermal necrolysis syndrome is an uncommon, acute, life-threatening, medication-induced disorder with a reported mortality rate of 20 to 60 percent. Different variables have been identified as risk factors. The extent to which these variables, when combined, affect the mortality and outcome in toxic epidermal necrolysis syndrome patients has not yet been reliably defined. Because of the high mortality rate, the logistic analysis of studied variables was performed to see whether a prognostic algorithm could be developed to aid the management of these patients. Thus, a retrospective review of 56 consecutive toxic epidermal necrolysis syndrome patients treated over a period of 13 years was undertaken in the authors' burn center. The demographics included age, sex, race, and total body surface area involved. The other variables studied were comorbidities, sepsis, steroid administration, and the interval between onset of rash and burn center admission. Data were subjected to Fisher's exact test and logistic analysis. Thirty-six patients (64.3 percent) were alive and 20 (35.7 percent) died. Univariate analysis indicated that the male/female ratio was 12:24 for survivors and 9:11 for nonsurvivors (p = 0.4). The white/nonwhite ratio was 80 percent for survivors and 54 percent for nonsurvivors (p = 0.58). The median age was 48.4 +/- 22.8 years (survivors, 41.7 +/- 22.0; nonsurvivors, 60.5 +/- 19.5; p = 0.002). Total body surface area involvement for survivors was 56.9 +/- 32 and 77.7 +/- 21 for nonsurvivors (p = 0.005). The presence of one or more comorbidities between the two groups differed (53 percent survivors and 90 percent nonsurvivors, p = 0.007), indicating eight times higher odds of dying in their presence. The average time between the onset of symptoms and admission to the burn unit was 5.25 +/- 3.4 days for survivors and 7.15 +/- 4.5 days for nonsurvivors (p = 0.08). The presence of sepsis (19.4 percent survivors, 95 percent nonsurvivors, p < 0.001) decreased odds for survival by a factor of 79. Steroids given as a single dose or multiple doses before the patient's transfer to the burn unit were not significantly associated with death (44 percent survivors, 65 percent nonsurvivors, p = 0.14). A multivariate logistic regression model yielded odds ratios of 1.11 (95 percent confidence interval, 1.03 to 1.19) for age in years, 304 (95 percent confidence interval, 8.83 to 10,400) for the presence of sepsis, and 1.03 (95 percent confidence interval, 0.99 to 1.08) for body surface area in percent. All those entering the burn unit with sepsis died. Equivalently, no survivors had sepsis before admission to the burn unit, whereas 55 percent of nonsurvivors had sepsis before admission and 40 percent developed sepsis after admission. When investigating the effect of age and sepsis, no patients over age 60 ever having sepsis survived, whereas all those who were under 60 and without sepsis survived. Likewise, all patients whose age was over 60 and whose total body surface area involved was over 60 percent died. The main factors contributing to the mortality from toxic epidermal necrolysis syndrome, when considering covariates separately, are the presence of sepsis at any time (odds ratio, 79), the presence of comorbidities (odds ratio, 8.05), age, and total body surface area, whereas multivariate models suggested age (odds ratio per year of additional age, 1.11), total body surface area (odds ratio per additional percent of body surface area, 1.03), and the presence of sepsis (odds ratio, 304). By using the actual coefficients in the logistic model, the log odds that the patient will die as the result of his or her condition can be summarized in the following formula: -11.5 + (10 percent of the patient's age + 3 percent of total body surface area + 5.75 if sepsis is present). The awareness of the importance of these covariates, and their early recognition as risk factors, should offer a focused approach to the patients' management and improve their outcome.

Entities:  

Mesh:

Year:  2002        PMID: 12172137     DOI: 10.1097/00006534-200209010-00008

Source DB:  PubMed          Journal:  Plast Reconstr Surg        ISSN: 0032-1052            Impact factor:   4.730


  11 in total

1.  New insights in toxic epidermal necrolysis (Lyell's syndrome): clinical considerations, pathobiology and targeted treatments revisited.

Authors:  Philippe Paquet; Gérald E Piérard
Journal:  Drug Saf       Date:  2010-03-01       Impact factor: 5.606

2.  Toxic epidermal necrolysis from a cigarette burn.

Authors:  Joshua R Parker; Ross P Berkeley
Journal:  West J Emerg Med       Date:  2010-05

3.  Ceftriaxone-induced toxic epidermal necrolysis mimicking burn injury: a case report.

Authors:  Sarit Cohen; Allan Billig; Dean Ad-El
Journal:  J Med Case Rep       Date:  2009-12-10

Review 4.  SJS/TEN 2017: Building Multidisciplinary Networks to Drive Science and Translation.

Authors:  Katie D White; Riichiro Abe; Michael Ardern-Jones; Thomas Beachkofsky; Charles Bouchard; Bruce Carleton; James Chodosh; Ricardo Cibotti; Robert Davis; Joshua C Denny; Roni P Dodiuk-Gad; Elizabeth N Ergen; Jennifer L Goldman; James H Holmes; Shuen-Iu Hung; Mario E Lacouture; Rannakoe J Lehloenya; Simon Mallal; Teri A Manolio; Robert G Micheletti; Caroline M Mitchell; Maja Mockenhaupt; David A Ostrov; Rebecca Pavlos; Munir Pirmohamed; Elena Pope; Alec Redwood; Misha Rosenbach; Michael D Rosenblum; Jean-Claude Roujeau; Arturo P Saavedra; Hajirah N Saeed; Jeffery P Struewing; Hirohiko Sueki; Chonlaphat Sukasem; Cynthia Sung; Jason A Trubiano; Jessica Weintraub; Lisa M Wheatley; Kristina B Williams; Brandon Worley; Wen-Hung Chung; Neil H Shear; Elizabeth J Phillips
Journal:  J Allergy Clin Immunol Pract       Date:  2018 Jan - Feb

Review 5.  Toxic epidermal necrolysis and Stevens-Johnson syndrome.

Authors:  Thomas Harr; Lars E French
Journal:  Orphanet J Rare Dis       Date:  2010-12-16       Impact factor: 4.123

6.  Severe desquamating disorder after liver transplant: toxic epidermal necrolysis or graft versus host disease?

Authors:  John T Schulz; Robert L Sheridan
Journal:  J Burns Wounds       Date:  2006-01-28

7.  Cephazolin-induced toxic epidermal necrolysis treated with intravenous immunoglobulin and N-acetylcysteine.

Authors:  Carlos Saavedra; Paola Cárdenas; Héctor Castellanos; Kateir Contreras; J R Castro
Journal:  Case Reports Immunol       Date:  2012-04-19

8.  Healthcare utilization and cost of Stevens-Johnson syndrome and toxic epidermal necrolysis management in Thailand.

Authors:  P Dilokthornsakul; R Sawangjit; C Inprasong; S Chunhasewee; P Rattanapan; T Thoopputra; N Chaiyakunapruk
Journal:  J Postgrad Med       Date:  2016 Apr-Jun       Impact factor: 1.476

9.  Toxic epidermal necrolysis and concurrent granulomatosis with polyangiitis (Wegener's granulomatosis). Management of a rare case and review of the literature.

Authors:  Stratos S Sofos; J Ewing; L C Hughes; M I James
Journal:  Scars Burn Heal       Date:  2016-04-22

10.  Epidermal necrolysis French national diagnosis and care protocol (PNDS; protocole national de diagnostic et de soins).

Authors:  Saskia Ingen-Housz-Oro; Tu-Anh Duong; Benoit Bensaid; Nathalia Bellon; Nicolas de Prost; Dévy Lu; Bénédicte Lebrun-Vignes; Julie Gueudry; Emilie Bequignon; Karim Zaghbib; Gérard Royer; Audrey Colin; Giao Do-Pham; Christine Bodemer; Nicolas Ortonne; Annick Barbaud; Laurence Fardet; Olivier Chosidow; Pierre Wolkenstein
Journal:  Orphanet J Rare Dis       Date:  2018-04-10       Impact factor: 4.123

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.